FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation by Wei Huang et al.
Huang et al. Molecular Cancer 2014, 13:150
http://www.molecular-cancer.com/content/13/1/150RESEARCH Open AccessFW-04-806 inhibits proliferation and induces
apoptosis in human breast cancer cells by
binding to N-terminus of Hsp90 and disrupting
Hsp90-Cdc37 complex formation
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Background: Heat shock protein 90 (Hsp90) is a promising therapeutic target and inhibition of Hsp90 will presumably
result in suppression of multiple signaling pathways. FW-04-806, a bis-oxazolyl macrolide compound extracted from
China-native Streptomyces FIM-04-806, was reported to be identical in structure to the polyketide Conglobatin.
Methods: We adopted the methods of chemproteomics, computational docking, immunoprecipitation, siRNA
gene knock down, Quantitative Real-time PCR and xenograft models on the research of FW-04-806 antitumor
mechanism, through the HER2-overexpressing breast cancer SKBR3 and HER2-underexpressing breast cancer
MCF-7 cell line.
Results: We have verified the direct binding of FW-04-806 to the N-terminal domain of Hsp90 and found
that FW-04-806 inhibits Hsp90/cell division cycle protein 37 (Cdc37) chaperone/co-chaperone interactions,
but does not affect ATP-binding capability of Hsp90, thereby leading to the degradation of multiple Hsp90 client
proteins via the proteasome pathway. In breast cancer cell lines, FW-04-806 inhibits cell proliferation, caused
G2/M cell cycle arrest, induced apoptosis, and downregulated Hsp90 client proteins HER2, Akt, Raf-1 and their
phosphorylated forms (p-HER2, p-Akt) in a dose and time-dependent manner. Importantly, FW-04-806 displays
a better anti-tumor effect in HER2-overexpressed SKBR3 tumor xenograft model than in HER2-underexpressed MCF-7
model. The result is consistent with cell proliferation assay and in vitro apoptosis assay applied for SKBR-3 and MCF-7.
Furthermore, FW-04-806 has a favorable toxicity profile.
Conclusions: As a novel Hsp90 inhibitor, FW-04-806 binds to the N-terminal of Hsp90 and inhibits Hsp90/Cdc37
interaction, resulting in the disassociation of Hsp90/Cdc37/client complexes and the degradation of Hsp90 client
proteins. FW-04-806 displays promising antitumor activity against breast cancer cells both in vitro and in vivo, especially
for HER2-overexpressed breast cancer cells.
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Heat shock protein (Hsp) 90 is a highly conserved
chaperone protein and among the most abundant pro-
teins found in eukaryotic cells [1-3]. Hsp90 exists as a
homodimeric structure in which individual monomers
are each characterized by three domains: an N-terminal
nucleotide binding domain (NBD), the site of ATP bind-
ing; the middle domain (MD), involved in ATP hydroly-
sis and the site of co-chaperone and client protein
binding; and a C-terminal dimerization domain (CDD),
the site of dimerization [4]. In addition to protecting
cells by correcting misfolded proteins, Hsp90 also plays
a key role in regulating the stability, maturation, and ac-
tivation of a wide range of client substrates, including
kinases, hormone receptors, and transcription factors
[5-8]. Most Hsp90 client proteins, such as epidermal
growth factor receptor 2 (HER2), Akt, Raf-1, Cdk4,
Bcr-Abl, and p53, are essential for cancer cell survival
and proliferation [9]. The chaperoning of these client
proteins is regulated by a dynamic cycle driven by ATP
binding to Hsp90 and subsequent hydrolysis of the pro-
tein [10]. Hsp90 requires a series of co-chaperones to
form a complex in order to function. These co-chaperones,
including cell division cycle protein 37 (Cdc37), Hsp70,
Hsp40, Hop, Hip, p23, pp5, and immunophilins, bind
to the super-chaperone complex and are released at
various time points to regulate the folding, assembly,
and maturation of Hsp90 client proteins [11]. To date,
the mechanisms of developed Hsp90 inhibitors have
greatly expanded, ranging from the Hsp90 protein func-
tion inhibitor to agents targeting the function of nucleo-
tides and co-chaperones crucially involved in regulating
the Hsp90 cycle [4].
We adopted chemoproteomics-based drug screening
[12,13] to identify clinical Hsp90 inhibitor candidates
among a series of natural product, extracted from plants,
Fungus, actinomycetes secondary metabolites and so on.
Specifically, the histidine-tagged yeast Hsp90 was loaded
onto an affinity column [12] and was subsequently
tested with these natural product. Mass spectrum ana-
lysis of the eluted solutions of proteins resulted in the
identification of the compounds bound to Hsp90. This
primary screening effort led to the discovery of FW-04-
806 as one of the potential Hsp90 inhibitors. Secondary
screening was conducted in parallel across multiple tar-
gets. The FW-04-806-loaded affinity columns were incu-
bated with the histidine-tagged NBD, MD, and CDD of
yeast Hsp90 to provide substantial binding information
and relative binding affinities.
FW-04-806, extracted from the China-native Strepto-
myces FIM-04-806 [14], is identical in structure to Con-
globatin [15] according to ultraviolet spectra, infrared
spectra, and NMR (1H and 13C) data and single-crystal
X-ray diffraction data [16]. Cell proliferation assays haveshown that FW-04-806 inhibits the growth of a human
chronic myelocytic leukemia K562 cell line with an IC50
of 6.66 μg/mL (almost 10 μM) [16]. Conglobatin has
been reported to be non-toxic at doses up to 1 g/kg
when administered to mice either orally or interperito-
neally [15]. In addition, our acute toxicity test showed
that mice survived after oral administration of 900 mg/kg
of FW-04-806. In the present study, we investigated the
effects of FW-04-806 on SKBR3 and MCF-7, HER2-
overexpressed and HER2-underexpressed human breast
cancer cell lines, respectively. Chemoproteomics and com-
putational approaches together confirmed that FW-04-806
bound to the N-terminus of Hsp90. A colorimetric assay
for inorganic phosphates and ATP pull-down assay showed
that FW-04-806 had little effect on Hsp90 ATPase activity
compared with 17AAG and did not affect ATP-binding of
Hsp90. Indeed, immunoprecipitation confirmed that FW-
04-806 disrupted Hsp90/Cdc37 chaperone/co-chaperone
interactions, leading to enhanced tumor-arresting activity–
and caused the degradation of Hsp90 client proteins. In
addition, FW-04-806 exhibited anticancer activity in an
in vivo breast cancer xenograft model, and no major tox-
icity was observed in the animals. These data suggest that
FW-04-806 is a potent Hsp90 inhibitor against human
breast cancer cells.
Materials and methods
Cell lines and reagents
SKBR3 and MCF-7 breast cancer cells were originally
obtained from American type culture collection. SKBR3
cells were cultured in Roswell Memorial Park Institute-
1640 medium and MCF-7 cells were grown in Dulbecco’s
modified Eagle medium. All media were supplemented
with 10% fetal bovine serum. The cells were maintained
under standard cell culture conditions at 37°C and 5% CO2
in a humid environment.
FW-04-806 (purity ≥98.5%) was produced by Fujian
Institute of Microbiology, China [14,16]. Recombinant
human Cdc37 was obtained from Sino Biological Inc.
MG132 was obtained from Sigma Aldrich. 17AAG
(Tanespimycin) was purchased from Selleckchem. MTS
was obtained from Promega. Primary antibodies against
Hsp90, Neu, Akt, Raf-1, His-probe and β-actin were pur-
chased from Santa Cruz Biotechnology. Primary anti-
bodies against phospho-Akt (Thr308), apoptosis and
phospho-HER2/ErbB2 antibody sampler kits containing
cleaved caspase-3 (Asp175), caspase-3, poly (ADP-ribose)
polymerase (PARP), cleaved PARP (Asp214), caspase-9,
cleaved caspase-9 (Asp330), caspase-7, cleaved caspase-7
(Asp 198), HER2/ErbB2 (D8F12), and phospho-HER2/
ErbB2 (Tyr1221/1222) were obtained from Cell Signaling
Technology. An Annexin V: fluorescein isothiocyanate
(FITC) Apoptosis Detection Kit Ι was purchased from
BD Biosciences.
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Recombinant vectors were constructed for histidine-
tagged full-length (1–732, 90 kDa), NBD (1–236, 25 kDa),
MD (272–617, 40 kDa), and CDD (629–732, 15 KDa)
of yeast Hsp90. The fusion proteins were expressed in
BL21(DE3) and purified via Ni-NTA column and gel
filtration [17].
Resin synthesis
CNBr-activated Sepharose™4B (GE Healthcare) was swelled
in 1 mM HCl and washed with coupling buffer (0.1 M
NaHCO3, 0.5 M NaCl, pH = 8.3).
For the Hsp90-loaded affinity column, 10 mg of pro-
tein per mL of medium was added to the resin, the
mixture was rotated overnight at 4°C, and then washed
with coupling buffer. Any remaining active groups were
blocked with capping solution (1 M ethanolamine) at
room temperature for 2 h. The resin was then treated
with a small molecule compound, rotated end to over-
end at room temperature for 4 h, and then washed away
of any excess compound. The resin was then washed
with three rounds of high pH buffer (0.1 M Tris–HCl,
0.5 M NaCl, pH = 8)/low pH buffer (0.1 M AcOH/NaA-
cOH, 0.5 M NaCl, pH = 4). Samples were desalted using
a Vivapure C18 spin column (Sartorius) before LC-MS
analysis [18].
For the drug-loaded affinity column, after the resin
was swelled, washed, and added into coupling buffer,
FW-04-806 was dissolved in dimethyl sulfoxide (DMSO)
and mixed into the resin (up to 10 μmoles per mL of
medium). The mixture was rotated end to overend for
4 h at room temperature, and then washed away of the ex-
cess ligand with coupling buffer. Any remaining active
groups were blocked with the capping solution for 2 h at
room temperature, and the column was equilibrated with
coupling buffer. The test proteins were added into the
resin, the mixture was rotated overnight at 4°C, and then
washed away of any excess proteins. The resin was added
to loading buffer, boiled for 10 min, separated with 10% so-
dium dodecyl sulfate polyacrylamide gel electrophoresis,
and then assayed by western blotting.
LC-MS detection
Samples were analyzed on Agilent 6410B Triple Quad-
rupole LC/MS system. Peptides were separated on a
BioBasic Picofrit C18 capillary column (New Objective).
Elution was performed with an acetonitrile gradient from 0
to 100% over 1 h with an overall flow rate of 1 mL/min.
ATP-Sepharose binding assay
ATP-Sepharose binding assay was modified base on pre-
vious protocol [19]. Different concentrations of FW-04-
806 or 17AAG were added into recombinant NBD Hsp90
protein (10 μg), and then mixtures were incubated with25 µL preequilibrated γ-phosphate-linked ATP-Sepharose
(Jena Bioscience GmbH) in 200 µL incubation buffer
(10 mM Tris–HCl, 50 mM KCl, 5 mM MgCl2, 20 mM
Na2MoO4 , 0.01% NP-40, pH 7.5) for 4 h at 4°C. The pro-
tein bound to Sepharose beads was separated with 10% so-
dium dodecyl sulfate polyacrylamide gel electrophoresis
and assayed with protein immunoblotting.
Colorimetric determination of ATPase activity
Malachite green reagent [20,21] was prepared on the day
of use and contained malachite green (0.0812%, w/v),
polyvinyl alcohol (2.32%, w/v, dissolves with difficulty
and requires heating), ammonium molybdate (5.72%, w/v,
in 6 M HCl), and argon water mixed in a ratio of 2:1:1:2 to
a golden yellow solution. The assay buffer consisted of
100 mM Tris–HCl, 20 mM KCl, and 6 mM MgCl2, with a
pH of 7.4. The experiments were performed in 100 μL of
test solution containing 80 μL of malachite green reagent.
The test solution contained 0.5 μM Hsp90 protein, 1 mM
ATP, and 25, 50, 100, or 200 μM FW-04-806 or vehicle
(DMSO).
Immunoprecipitation
Samples (500 μg of total protein) were incubated over-
night with 2 μg of primary antibody at 4°C, after which
20 μL of protein A Mag Sepharose™ (GE Healthcare, UK)
was added to the mixture, which was then incubated for
2 h at 4°C. The immunoprecipitated protein complexes
were washed once with lysis buffer and twice with ice-
cold PBS. After the supernatant was discarded, the anti-
body/protein complexes were resuspended in 30 μL of
loading buffer and boiled for 5 min. The entire sample
was separated with 10% sodium dodecyl sulfate poly-
acrylamide gel electrophoresis and assayed with protein
immunoblotting.
Small interfering RNA (siRNA) gene knockdown
SKBR3 cells were seeded in antibiotic-free normal growth
medium supplemented with fetal bovine serum. Single
siRNA oligonucleotides targeting human Hsp90α/β
(sc-35608, Santa Cruz Biotechnology) and control siRNA
(sc-37007) were diluted in siRNA Transfection Medium
(sc-36868) and mixed with siRNA Transfection Reagent
(sc-29528) according to the manufacturer’s protocol.
SKBR3 cells were incubated with the transfection com-
plexes for 6 h and in the normal growth medium for
48 h. Cells then were treated with DMSO or FW-04-806
for 24 h before cell lysates were prepared and analyzed
with western blot.
Quantitative real-time PCR
Total RNA extraction was performed with TRIzol reagent
(Life Technologies Corporation), and first strand cDNA
was synthesized using 1 μg of total RNA (concentrations
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treated with avian myeloblastosis virus (AMV) reverse
transcriptase (Promega) according to the manufacturer’s
instructions. Quantitative real-time reverse transcription
polymerase chain reaction (RT-PCR) analysis was per-
formed in triplicate with FastStart Essential DNA Green
Master (Roche) using LightCycler 96 (Roche). The ΔΔCT
method was used to calculate relative expression. Primer
sequences used in RT-PCR for human Akt (forward 5′-
TTGAGAGAAGCCACGCTGT-3′ and reverse 5′-CGGA
GAACAAACTGGATGAA-3′), HER2 (forward 5′-TGC
TGTCCTGTTCACCACTC-3′ and reverse 5′-TGCTTT
GCCACCATTCATTA-3′), Raf-1 (forward 5′-CACCTC
CAGTCCCTCATCTG-3′ and reverse 5′-CTCAATCAT
CCTGCTGCTCA-3′), Hsp90 (forward 5′-GGGCAAC
ACCTCTACAAGGA-3′ and reverse 5′-ATCAACTGGG
CAATTTCTGC-3′), GAPDH (forward 5′-AGAAGGCTG
GGGCTCATTTG-3′ and reverse 5′-AGGGGCCATCCA
CAGTCTTC-3′).
MTS assay
Cells (5 × 103/well) were seeded into 96-well plates
and treated with 10, 20, or 40 μM of FW-04-806 or
vehicle (DMSO) for 48 h. At the end of the incuba-
tion period, cell viability was assessed by MTS assay
(Promega)according to the manufacturer’s instruction.
The number of living cells is proportional to the absorb-
ance at 490 nm. The results are presented as means ±
standard deviation from three independent experiments.
Inhibition graphs used mean values obtained from each
concentration relative to control values, and the half
maximal inhibitory concentration (IC50) were calculated
by SPSS.
Cell cycle analysis
Cells were seeded in 6-well plates and treated with vari-
ous doses of FW-04-806 or vehicle (DMSO) for 24 h.
The cells were harvested, washed with phosphate-
buffered saline (PBS), and fixed with 70% ethanol at
−20°C overnight. After an additional washing, cells were
incubated with RNase A (20 μg/mL) at 37°C for 30 min,
stained with propidium iodide (100 μg/mL; Sigma Al-
drich) for 10 min, and analyzed with flow cytometry (BD
FACSC autoTM II).
Apoptosis assay
Apoptosis was determined with the Annexin-V: FITC
Apoptosis Detection Kit Ι (BD Biosciences) according to
the manufacturer’s protocol. Briefly, the vehicle control
(DMSO) and FW-04-806-treated cells were collected via
centrifugation and washed once with PBS. The cells
were subsequently stained with fluorescein and propi-
dium iodide for 15 min at room temperature and ana-
lyzed with flow cytometry.Western blot analysis
After treatment, cancer cells were collected, washed with
PBS, lysed with NP-40 lysis buffer (50 mmol/L Tris
pH 8.0, 150 mmol/L NaCl, and 1% NP-40) supplemented
with phenylmethanesulfonyl fluoride (Sigma Aldrich) and
PhosSTOP (Roche Diagnostics) for 30 min at 4°C, and
centrifuged at 12,000 × g for 10 min. The supernatant
was collected as the total protein extract. Protein concen-
tration was estimated using a Pierce BCA Protein Assay
Kit (Thermo Scientific, USA) according to the manufac-
turer’s protocol. Equal amounts of protein were analyzed
with sodium dodecyl sulfate polyacrylamide gel electro-
phoresis. Thereafter, proteins were transferred to polyvi-
nylidene fluoride membranes and blotted with specific
primary antibodies. Proteins were detected via incu-
bation with horseradish peroxidase-conjugated secondary
antibodies and visualized with SuperSignal WestPico
(Thermo Scientific, USA). All the western blot detections
were repeated three or more times.
Animals, tumor xenografts, and test agents for in vivo
studies and efficacy
BALB/c (nu/nu) athymic mice were purchased from
Shanghai SLAC Laboratory Animal Co. LTD. For SKBR3
and MCF-7 xenografts, 6-mm3 tumor fragments were
implanted into the subcutaneous tissue of the axillary
region using a trocar needle, and the animals were ran-
domly divided into groups (n = 6) when the bearing
tumor reached approximately 20 mm3. FW-04-806 was
suspended at the desired concentration for each dose
group in an aqueous vehicle containing 10% ethanol,
10% polyethylene glycol 400, and 10% Tween 80. The con-
trol group was given 0.4 mL/mouse vehicle solution i.g.;
mice in other groups were given 50, 100, or 200 mg/kg of
FW-04-806. Doxorubicin hydrochloride (ADM, Shenzhen
Main Luck Pharmaceuticals Inc, China) was purchased as
10 mg injections and diluted with saline as necessary to
achieve the prescribed concentration.
Tumor volumes were calculated using the following
ellipsoid formula: [D × (d2)]/2, in which D is the large
diameter of the tumor, and d is the small diameter.
Tumor growth inhibition was determined using the fol-
lowing formula: 100 % × [(WC–WT)/WC], in which WC
represents mean tumor weight of a vehicle group, and
WT represents mean tumor weight of a treated group.
All animal experiments were approved by animal care
and use committee, Fujian Medical University, China.
Immunohistochemistry
Immunohistochemistry was performed on tumors har-
vested from each xenograft group treated with FW-04-806
or vehicle. Tumors were cut into 3- to 5-mm pieces, fixed
in 4% paraformaldehyde for 6 h, dehydrated, paraffin-
imbedded, sectioned, and placed on slides (Zhongshan
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performed in 0.1 M citrate buffer, pH 6, at 100°C for
2 min. After incubation with 3% hydrogen peroxide for
10 min and three washes with PBS buffer, primary anti-
body Neu (rabbit poly-clonal, Santa Cruz Biotechnology,
sc-284) was used at a dilution of 1:200 for 2 h. The slides
were sequentially incubated with biotin-conjugated
secondary antibodies (1:200) followed by horseradish
peroxidase-conjugated streptavidin (1:100). The first step
lasted 20 min and the second step lasted 30 min at 37°C,
with 5 min PBS washes three times for each step. The reac-
tions were revealed using diaminobenzidine substrate, and
the slides were then washed under running tap water. Con-
trast was applied with hematoxylin, and the slides were
mounted in Canadian balsam and observed with a light
microscope.
Statistical analysis
Analysis of variance was used for comparisons across mul-
tiple groups. The data are reported as means ± standard
deviation. Statistical analysis was conducted using PASW-
statistics 18 (SPSS, Inc); p < 0.05 was considered statistically
significant.
Results
FW-04-806 binds to the N-terminal of Hsp90
FW-04-806, extracted from the China-native Streptomyces
FIM-04-806 and identical to Conglobatin [16], had been
discovered to be one of the potential Hsp90 inhibitors
in the initial screening (Figure 1A). Secondly, the FW-
04-806-loaded affinity columns were separately incu-
bated with the histidine-tagged full-length, NBD, MD,
and CDD of yeast Hsp90. This affinity-based screen
showed that FW-04-806 bound to NBD of Hsp90, but
not MD or CDD (Figure 1B). To define physiologically
relevant associations with Hsp90, we added free soluble
FW-04-806 up to 10 μM into proteins prior to expos-
ure to the drug-loaded affinity resin [12]. The competi-
tion results showed that the soluble FW-04-806 can
compete the binding of Hsp90 protein from cell lysate,
full-length and NBD recombinant protein to the resin
compared with the no free ligand adding control, which
confirmed the specific interaction between NBD Hsp90
and FW-04-806 (Figure 1C).
We then used Molsoft ICM 3.5a to model the inter-
action between Hsp90 (Protein Data Bank ID 2CCS) and
FW-04-806 (Figure 1D). In contrast to the binding of
GA with N-terminal Hsp90 (Figure 1E), FW-04-806
docked to different sites of N-terminal Hsp90, close to
helix 4 or 5 (Figure 1F). Compared with the Hsp90/
Cdc37 complex (PDB ID 2K5B), FW-04-806 bound to
similar sites with the co-chaperone Cdc37 (Figure 1G).
Electrostatic interactions form between the charge
group of FW-04-806 and the amino group of residueR46/E47 of Hsp90 (Figure 1H). Hydrogen bonds are
also formed between FW-04-806 and residues S50 and
N51 in Hsp90 (Figure 1I). Specifically, hydrophobic
packing interactions form between residue Q133 and
the hydrophobic parts of FW-04-806 (Figure 1H). Of
particular interest, FW-04-806 and Cdc37 share com-
mon binding sites at residues Q133 and E47/R46 of
Hsp90 (Figure 1H).
The results of the chemoproteomics screening and
docking models provide evidence that FW-04-806 is
a potential inhibitor of Hsp90 by binding to the NBD of
Hsp90.
FW-04-806 does not affect ATP-binding capability of Hsp90,
but inhibits Hsp90/Cdc37 chaperone/co-chaperone
interactions
Most Hsp90 inhibitors, e.g.,17AAG, inhibit Hsp90
chaperone function by binding to Hsp90 N-terminal
ATP pocket to prevent the maturation of Hsp90 client
proteins [22]. Recombinant yeast NBD Hsp90 proteins
were added with different concentrations of FW-04-
806 or 17AAG to detect the effect of drugs on ATP-
binding capacity of Hsp90. FW-04-806 (up to 40 μM)
was unable to downregulate the amount of ATP-bound
Hsp90, compared with the definite decrement caused by
17AAG, which suggested that FW-04-806 was not likely
to decrease Hsp90 ATP-binding capacity (Figure 2A).
In the colorimetric assay for inorganic phosphates to
measure ATPase activity of Hsp90, FW-04-806 had lit-
tle effect on the ATPase activity of Hsp90 and showed
no dose-dependence, while the positive control 17AAG
showed evident inhibition in a dose-dependent manner
(Figure 2B).
According to computational docking, FW-04-806
inhibit Hsp90 chaperon capacity probably by disrupt-
ing the Hsp90 and co-chaperon Cdc37 complex, so
we conducted the in vitro His-resin pull-down test
by mixture recombinant Cdc37 and His tag Hsp90
protein with different concentrations of FW-4-806.
The result showed FW-04-806 would hinder the inter-
action between Cdc37 and Hsp90 in a dose dependent
manner (Figure 2C). Furthermore, we also immuno-
precipitated Cdc37 and Hsp90 from whole-cell lysates
of SKBr3, and analyzed the variations of bound Cdc37,
Hsp90 and HER2 proteins. With the increment of
FW-04-806, when Cdc37 was immunoprecipitated, the
protein levels of bound Hsp90 and HER2 decreased.
Vise verse, when Hsp90 was immunoprecipiated, the
protein levels of bound Cdc37 and HER2 were de-
creased. These data indicated that the Hsp90/Cdc37/
HER2 chaperone complex was damaged by FW-04-806
(Figure 2D).
The effect of FW-04-806 on Hsp70, Hsp90, and Cdc37
was also tested using 17AAG as a positive control
Figure 1 FW-04-806 is identified as an Hsp90 binding medicine. (A) LC/MS spectrum detects the compound eluted from the Hsp90-loaded
affinity column. Peak a and b represent elution samples from the control and FW-04-806 bound Hsp90-loaded column, respectively. MS spectrum
displays M/z of Peak b. (B) Western blot confirms FW-04-806 binds to NBD of Hsp90. The “–” symbol represents no drug-loaded affinity column,
the “+” symbol represents the drug-loaded affinity column. The test proteins are SKBR3 cell lysate, His-tagged yeast Hsp90, and His-tagged NBD,
MD, CDD of yeast Hsp90. Human Hsp90 Antibody and His-probe antibody were used respectively. (C) Soluble FW-04-806 was added into SKBR3
cell lysate, His-tagged full-length, NBD, MD and CDD of yeast Hsp90 up to 10 μM before incubation with drug-loaded affinity resin. Picture a and c
show Human Hsp90 Antibody; picture b and d show His-probe antibody. (D) Molecular structure of FW-04-806. (E) Geldanamycin (GA) binds
to N-terminal Hsp90 (Protein Data Bank [PDB] ID 1YTE) in the ATP binding pocket. Hsp90 is shown in the green ribbon view; GA is shown
in stick view. (F) FW-04-806 docks to N-terminal Hsp90 (PDB ID 2K5B). N-Hsp90 is shown in green ribbon view; FW-04-806 is shown in stick view.
(G) FW-04-806 binds to the N-Hsp90/Cdc37 complex (PDB ID 1US7). N-Hsp90 is shown in green ribbon view; Cdc37 is shown in yellow ribbon view;
FW-04-806 is shown in orange ball view. (H) Stick view of FW-04-806 bound to N-Hsp90/Cdc37 complex. N-Hsp90 is shown in green stick view;
FW-04-806 is shown in white stick view; Cdc37 is shown in blue stick view. (I) Stick views of FW-04-806 and N-Hsp90 in white and green, respectively.
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distinct change according to a drug concentration gradient,
whereas Hsp70, a marker of Hsp90 inhibition, the protein
level was greatly induced by treatment with 17AAG orFW-04-806. Furthermore, following depletion of Hsp90
protein by RNAi, FW-04-806 could not induce further
HER2 protein degradation, suggested that Hsp90 protein
was a direct target of FW-04-806 (Figure 2F).
Figure 2 FW-04-806 inhibits Hsp90/Cdc37 chaperone/co-chaperone interactions. (A) FW-04-806 (10, 20, 40 μM) was added into recombinant
NBD Hsp90 protein did not affect ATP binding capacity of Hsp90, while 17AAG (0.5, 1 μM) decreased ATP binding. Western blot was analyzed with
His-probe antibody. (B) FW-04-806 had little effect on Hsp90 ATPase activity as determined by the malachite green reagent. The assay used 0.5 μM
Hsp90 protein, 1 mM ATP, and FW-04-806 or 17AAG at 25, 50, 100, or 200 μM, or vehicle (DMSO) at 620 nm. Results are presented as means ± SD of
three independent experiments. *p < 0.05: significant difference from control by analysis of variance; **p < 0.01: very significant difference from
control by analysis of variance. (C) FW-04-806 directly affect Hsp90-Cdc37 interaction in Pull-down assay. 400 ug of purified Hsp90 (His-tag)
protein was bound with Ni-NTA resin and divided into four groups evenly with the addition of recombinant Cdc37 protein 50 μg each and
FW-04-806 0, 10, 20, 40 μM, respectively. After incubation and wash, The resins were boiled with loading buffer and analyzed by western blotting,
His-probe antibody and Cdc37 antibody was used respectively. (D) SKBR3 cells were treated with FW-04-806 or DMSO for 24 h. Cdc37 or Hsp90
were immunoprecipitated from whole-cell lysates (500 μg each) with an anti-Cdc37 or anti-Hsp90 antibody respectively, then analyzed by
immunoblotting with antibody against Hsp90, Cdc37 and HER2 (E) SKBR3 cells were treated with FW-04-806 at 10, 20, 40 μM for 24 h;
17AAG was used as a positive control at 1 and 2 μM. Hsp70, Hsp90, and Cdc37 protein level were analyzed with western blotting using
relevant antibodies. (F) SKBR3 cells were transiently transfected with control siRNA or Hsp90 siRNA for 48 h. Whole-cell lysates were analyzed with
western blotting against HER2, Hsp90, and β-actin.
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induces proteasome-dependent degradation
We tested the effect of the compound on the Hsp90
client proteins in breast cancer cells. SKBR3 and
MCF-7 cells were treated with FW-04-806 at variousconcentrations and durations. FW-04-806 reduced the
levels of the client proteins HER2, p-HER2, Raf-1, Akt,
and p-Akt in a dose and time-dependent manner in
SKBR3 cells (Figure 3A and B). The same tendency was
observed in MCF-7 cells (Figure 3C and D), but no
Figure 3 FW-04-806 induces proteasome-dependent degradation and decreases Hsp90 client protein level. (A) SKBR3 cells were treated
by FW-04-806 at 10, 20, 40 μM for 24 h; HER2, phosphorylated HER2 (p-HER2), Raf-1, Akt, and phosphorylated Akt (p-Akt) protein levels were
analyzed with western blotting. (B) SKBR3 cells were treated with 20 μM of FW-04-806 for 0, 3, 6, 12, or 24 h; HER2, p-HER2, Raf-1, Akt, and
p-Akt protein levels were analyzed with western blot. (C) MCF-7 cells were treated by FW-04-806 at 10, 20, 40 μM for 24 h; western blot detected
the protein expression of Raf-1, Akt, and p-Akt. (D) MCF-7 cells were treated with 20 μM FW-04-806 for 0, 3, 6, 12, or 24 h; western blot detected
the protein expression of Raf-1, Akt, and p-Akt. (E) SKBR3 was pretreated with 1 μM of MG132 for 2 h in the presence or absence of 20 μM
of FW-04-806 for an additional 12 h. Whole-cell lysates were subjected to western blot analysis using antibodies against HER2, Raf-1, Akt, and
β-actin. (F) SKBR3 was treated with DMSO or FW-04-806 at 10, 20, 40 μM for 24 h. The total RNA was extracted for quantitative Real-time
PCR of AKT, HER2, Raf-1 and Hsp90, using GAPDH as control. *P < 0.05: significant difference from control by analysis of variance; **P < 0.01:
very significant difference from control by analysis of variance.
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cell.
In addition, degradation was completely blocked by
treatment with the proteasome inhibitor MG132, indi-
cating that the proteasome system was responsible for
FW-04-806-induced client protein degradation (Figure 3E).Furthermore, we carried out quantitative real-time
PCR to test the mRNA expression levels of Akt, HER2,
Raf-1, Hsp90, using GAPDH as control. The result
showed that FW-04-806 did not block the transcrip-
tion, but directly acting through inhibition of Hsp90
(Figure 3F).
Figure 4 (See legend on next page.)
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Figure 4 FW-04-806 inhibits growth, induces cell cycle arrest, induces apoptosis, and downregulates the expression of anti-apoptotic
proteins. (A) SKBR3 and MCF-7 cells were grown for 48 h in the absence or presence of increasing concentrations of FW-04-806. Cell growth
inhibition was measured with MTS and was expressed as a percentage of vehicle-treated control; results are presented as means ± SD of three
independent experiments. *p < 0.05: significant difference from control by analysis of variance; **p < 0.01: very significant difference from control
by analysis of variance. (B) SKBR3 and MCF-7 cells were treated with increasing doses of FW-04-806 or vehicle DMSO for 24 h. The cells were
then fixed with 70% ethanol at −20°C overnight, incubated with RNase A at 37°C for 30 min, stained with propidium iodide for 10 min, and
analyzed with flow cytometry. (C) SKBR3 and MCF-7 cells were treated with FW-04-806 for 24 h, and apoptotic cell death was detected by staining
cells with an Annexin-V: FITC Apoptosis Detection Kit for analysis with flow cytometry. (D) SKBR3 and MCF-7 cells were treated with increasing
doses of FW-04-806 for 24 h, and the apoptosis signal proteins were detected with western blot analysis using an Apoptosis Antibody Sampler Kit;
β-actin was used as a loading control.
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induces apoptosis, and downregulates the expression
of anti-apoptotic proteins
The effects of FW-04-806 on cell proliferation were
assessed with an MTS assay. The proliferation of SKBR3
and MCF-7 cells was markedly inhibited by FW-04-806,
with IC50 values of 12.11 and 39.44 μM, respectively
(Figure 4A).
Compared to vehicle-only treated controls, FW-04-
806-treated cells displayed obvious arrest of cells in the
G2/M phase after 24 h. The increase in the G2/M cell
population was accompanied by a concomitant decrease
in the population in the S and G0/G1 phases of the cell
cycle (Figure 4B).
SKBR3 and MCF-7 cells were treated with FW-04-806
for 24 h and analyzed for apoptotic cell death using an
Annexin-V: FITC Apoptosis Detection Kit. The results
revealed a dose-dependent induction of necrotic/late
apoptotic cell death in both cell lines (Figure 4C).
Caspases, a family of cysteine acid proteases, are cen-
tral regulators of apoptosis. Western blot analysis re-
vealed that FW-04-806 caused dose-dependent changes
in the levels of apoptosis signal proteins. The initiator
caspase 9, effector caspases (3 and 7), and the PARP
precursor exhibited similar reductions, which were ac-
companied by increases in the levels of their cleaved
fragments (Figure 4D). These data indicate that FW-04-
806 induced apoptosis through caspase-dependent path-
ways in SKBR3 and MCF-7 cells.
FW-04-806 inhibits the tumor growth of SKBR3 and
MCF-7 tumor xenograft models
SKBR3 and MCF-7 human breast cancer xenografts
were established to assess the chemotherapeutic poten-
tial of FW-04-806. The antitumor activity of FW-04-806
at three doses (50, 100, and 200 mg/kg per dose i.g., q3d)
were determined. ADM (4 mg/kg per dose i.p., q3d)
was used as a positive control. The results demon-
strated that FW-04-806 inhibited tumor growth in the
SKBR3 and MCF-7 xenograft models in a dose-dependent
manner (Figure 5A and B). Compared with the vehicle
group, the three increasing doses of FW-04-806 showed,respectively, inhibition of tumor growth at a rate of 39.1%
(P = 0.009), 52.7% (P = 0.003), and 67.5% (P = 0.0007) in
the SKBR3 cell line groups and 27.3% (P = 0.021), 39.8%
(P = 0.004), 54.3% (P = 0.001) in the MCF-7 cell line
groups. Notably, the antitumor activity of high-dose FW-
04-806 (0.37 ± 0.04 g, 67.5%) was better than positive
control group(0.39 ± 0.04 g, 64.9%, P = 0.0008).
All animals survived FW-04-806 treatment without
appreciable adverse effects in terms of body weight loss
or other signs of toxicity during the treatment (Figure 5C
and D). Liver and renal function was similar between
FW-04-806-treated and control mice. Additionally, lung,
liver, heart, and kidneys of mice showed no histological
abnormalities at the end of drug treatment (data not
shown). This outcome demonstrates that FW-04-806
was well tolerated.
Immunohistochemistry confirmed greater decreases
in HER2 expression in the FW-04-806-treated groups
compared with the vehicle groups in SKBR3 tumor
xenografts; the reductions showed dose dependency
(Figure 5E). The changes in HER2, p-HER2, Raf-1,
Akt, and p-Akt protein levels were then checked in the
excised tumor tissues. Western blotting results showed
that high doses of FW-04-806 decreased the levels of
p-HER2 and p-Akt in the same proportion as reductions in
total HER2, Raf-1, and Akt in both SKBR3 and MCF7
model (Figure 5F and G). The results coincided with the
western blot results in vitro (Figure 3).
Discussion
Most Hsp90 inhibitors have been developed to inhibit
Hsp90 chaperone function by binding to Hsp90 at the
N-terminus and blocking the ATP/ADP pocket [22]. The
antibiotics benzoquinone ansamycins, such as geldanamy-
cin (GA) and its derivative 17-allyamino-geldanamycin
(17AAG), were the first identified Hsp90 inhibitors [23].
The binding of GA in the N-terminal ATP pocket arrests
the catalytic cycle of Hsp90 in the ADP-bound con-
formation, inactivating chaperone activity, which results
in the ubiquitination and proteasomal degradation of cli-
ent proteins [24-26]. Although GA and its derivatives have
exhibited potent anticancer effects, severe hepatotoxicity
Figure 5 FW-04-806 inhibits the tumor growth of SKBR3 and MCF-7 tumor xenograft models. (A and B) SKBR3 and MCF-7 tumor xenograft
nude mice were randomized into treatment groups (n = 6/group) and received FW-04-806 at doses of 50, 100, 200 mg/kg i.g., q3d (in a vehicle of
10% ethanol, 10% polyethylene glycol 400, and 10% Tween 80) or ADM at doses of 4 mg/kg i.p., q3d, until the day that the tumor sizes of the
vehicle control groups reached approximately 1000 mm3. Tumors were weighed to evaluate the anticancer activity of FW-04-806. Data are
presented as means ± SD (n = 6, P < 0.01). (C and D) Mouse body weight was measured twice a week. (E) HER2 expression in SKBR3 tumors.
Picture a shows vehicle controls; picture b, c and d show 50, 100 and 200 mg/kg groups, respectively. (F) Tumor tissues excised from the SKBR3
xenograft mice were lysed; changes in the levels of in HER2, p-HER2, Raf-1, Akt, and p-Akt protein were tested. (G) Tumor tissues excised from the
MCF-7 xenograft mice were lysed; western blot detected the changes in the levels of in Raf-1, Akt, and p-Akt protein expressions.
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showed that a natural product, FW-04-806, a novel
Hsp90 inhibitor, inhibits Hsp90 function through binding
the N-terminus of Hsp90 and blocking formation of the
Hsp90-Cdc37 complex (Figures 1 and 2) in an ATP-
binding independent manner, therefore the mechanism
of action is clearly different from those classic Hsp90
inhibitors.The wide-ranging functions of Hsp90 require a series
of co-chaperones to drive the chaperone cycle to com-
pletion [22]. Therefore, affecting co-chaperone function
by specifically targeting various co-chaperone/Hsp90 in-
teractions may offer an alternative way to achieve the
outcomes of direct Hsp90 inhibition [28,29]. Cdc37 is an
essential co-chaperone and functions as an adaptor in
the recruitment of client proteins, predominantly kinases
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receptor tyrosine kinases (Src), lymphocyte-specific pro-
tein tyrosine kinase, Raf-1, and CDK4, to Hsp90 [30-34].
The targeting of the Hsp90/Cdc37 interaction is a po-
tential alternative to direct Hsp90 inhibition that may
offer greater specificity and an improved side effect pro-
file owing to the elevated expression of Cdc37 in cancer
[5]. To date, only a few medicines were discovered to
target Hsp90/Cdc37 interaction. Celastrol is a quinine
methide triterpene extracted from Tripterygium wilfor-
dii. It has recently been found to disrupt Hsp90/Cdc37
association, which results in the degradation of AKT and
CDK4 and the induction of apoptosis in the pancreatic
cell line Panc-1 [28]. But recent nuclear magnetic reson-
ance (NMR) studies have suggested that celastrol binds to
Cdc37 instead of the Hsp90 N-terminus domain [35,36].
Withaferin A (WA), a steroidal lactone extracted from
Withania somnifera, disrupts the Hsp90/Cdc37 complex
by binding to the C-terminus domain of Hsp90 and chan-
ging Hsp90 conformation to prevent Cdc37 binding
[37,38]. Sulforaphane, a dietary component from broccoli
sprouts, blocks Hsp90-Cdc37 complex by interacting with
Ile amino acids residues of the N-terminal and middle do-
main of Hsp90 [19]. Our work here found a new medicine
targeting Hsp90/Cdc37 interaction with new mechanism
which is quite different with the medicines above.
We have showed that FW-04-806 is a Hsp90 inhibitor
that directly binds to the N-terminus of Hsp90 and at-
tenuates Hsp90/Cdc37 chaperone/co-chaperone interac-
tions, leading to the degradation of multiple Hsp90
client proteins via the proteasome pathway, which may
be the primary mechanism mediating the anticancer ac-
tivities of FW-04-806. The antagonistic efficacy of FW-
04-806 against human breast cancer lines has been in-
vestigated at both the molecular and cellular levels. It has
been demonstrated that FW-04-806 inhibits the HER2-
overexpressed and HER2-underexpressed breast cancer
cell lines SKBR3 and MCF-7 in a dose and time-dependent
manner with IC50 values of 12.11 and 39.44 μM, respect-
ively. Moreover, it was shown that FW-04-806 arrests cell
cycle progression and induces programmed cell death.
It has further been shown that FW-04-806 displays an-
titumor effects in an in vivo animal model as well as in
the in vitro settings previously described. Studies were
conducted to investigate the effect of FW-04-806 on tu-
mors derived from cancer cell lines SKBR3 and MCF-7.
High dose administration of FW-04-806 displayed an in-
hibitory effect on SKBR3-derived tumors was more pref-
erable in both the antitumor activity and mouse body
weight than that of ADM, one of the most widely used
chemotherapy drugs. Importantly, we found that FW-04-
806 displays a better antitumor effect in SKBR3 tumor
xenograft model than in MCF-7. The result is consistent
with cell proliferation assay and in vitro apoptosis assayapplied for SKBR3 and MCF-7. As these cell lines are
HER2-overexpressed and HER2-underexpressed respect-
ively, and HER2 is among the most sensitive Hsp90 clients
[39], we assume that FW-04-806 has a preferential inhibi-
tory effect on HER2-overexpressed cancer cells. This as-
sumption is now being tested on other cancer cell lines.
Moreover, mice survived at the dose of 900 mg/kg in the
acute toxicity test, and all xenografts mice had no appre-
ciable adverse effects during the treatment. No histological
abnormalities was found in lung, liver, heart, and kidneys
of mice (Data not shown), suggested that FW-04-806 had
a favorable toxicity profile.
Conclusion
In conclusion, as a novel Hsp90 inhibitor, FW-04-806
binds to the N-terminal of Hsp90 and inhibits Hsp90/
Cdc37 interaction, resulting in the disassociation of
Hsp90/Cdc37/client complexes and the degradation
of Hsp90 client proteins. FW-04-806 displays promising
antitumor activity against breast cancer cells both in vitro
and in vivo, especially for HER2-overexpressed breast can-
cer cells. Our observations provide a basis for the further
development of Hsp90 or HER2 targeted therapy for pa-
tients with breast cancer.
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